NASA's International Space Station has become a hub for groundbreaking medical research that's set to revolutionize cancer treatment. The unique conditions of microgravity have enabled scientists to grow larger, more uniform crystals than ever before, which could lead to significant improvements in medication delivery.
In collaboration with pharmaceutical giant Merck, researchers on the space station have been studying protein crystal growth. This work has provided early insights into the structure and size of particles that are best suited for developing a new formulation of pembrolizumab - a cancer medicine approved by the FDA in September.
The new subcutaneous injection method promises to save patients time and money, reducing treatment time from up to two hours to just one minute every three weeks. This is a major breakthrough for those who currently rely on intravenous infusion therapy, which can be a lengthy and costly process.
Merck has been conducting crystal growth experiments on the space station since 2014, working to better understand how crystals form - including the monoclonal antibodies used in cancer treatments. The absence of gravity's physical forces in microgravity allows scientists to grow higher-quality crystals than ever before, making it possible to develop more effective medication formulations.
The research aboard the space station has provided valuable insights into how gravity influences crystallization, which could lead to significant improvements in drug development and structural modeling. As NASA continues to push the boundaries of human knowledge, its partnership with private industry is growing a commercial economy in low Earth orbit - one that will pave the way for future human exploration of the Moon and Mars.
In collaboration with pharmaceutical giant Merck, researchers on the space station have been studying protein crystal growth. This work has provided early insights into the structure and size of particles that are best suited for developing a new formulation of pembrolizumab - a cancer medicine approved by the FDA in September.
The new subcutaneous injection method promises to save patients time and money, reducing treatment time from up to two hours to just one minute every three weeks. This is a major breakthrough for those who currently rely on intravenous infusion therapy, which can be a lengthy and costly process.
Merck has been conducting crystal growth experiments on the space station since 2014, working to better understand how crystals form - including the monoclonal antibodies used in cancer treatments. The absence of gravity's physical forces in microgravity allows scientists to grow higher-quality crystals than ever before, making it possible to develop more effective medication formulations.
The research aboard the space station has provided valuable insights into how gravity influences crystallization, which could lead to significant improvements in drug development and structural modeling. As NASA continues to push the boundaries of human knowledge, its partnership with private industry is growing a commercial economy in low Earth orbit - one that will pave the way for future human exploration of the Moon and Mars.